CTIS2023-508314-42-00招募中1 期
IMMUWHY - A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of care - IMMUWHY
Institut fuer Klinische Krebsforschung IKF GmbH0 个研究点目标入组 66 人开始时间: 2023年10月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Fully-informed written consent and locally required authorization (European Union [EU]: General Data Privacy Regulation (GDPR)) obtained from the patient prior to performing any protocol-related procedures, including screening evaluations., Adequate hepatic function (with stenting for any obstruction, if required) including the following: o Serum bilirubin = 1.5 x institutional upper limit of normal (ULN); o AST (SGOT) / ALT (SGPT) = 2.5x institutional ULN (NOTE: if liver metastases are present AST / ALT must be = 5x institutional ULN; o prothrombin time ?60%; o albumin ?30 g/L., Female patients with reproductive potential must have a negative urine or serum pregnancy test within 7 days prior to start of trial., Evidence of post-menopausal status or negative urinary or serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: o Women <50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy). o Women =50 years of age would be considered post-menopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy-induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy)., The patient is willing and able to comply with the protocol for the duration of the study, including hospital visits for treatment and scheduled follow-up visits and examinations., Must have a life expectancy of at least 12 weeks., If patient has concurrent Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, meets the following criteria: - Patients with HBV or HCV infection should be monitored for viral levels during study participation. - Patients with detectable hepatitis B surface antigen (HBsAg) or detectable HBV DNA should have HBV DNA < 100 IU/ml and should be managed per local treatment guidelines. Controlled (treated) hepatitis B subjects will be allowed if they started treatment at the time point of enrollment into the study by the latest and treatment is continued during study participation and for = 6 months after end of study treatment. - HCV patients with advanced BTC are mostly not treated for their HCV infection. However, patients treated for HCV are considered suitable for inclusion if antiviral therapy has been completed = 30 days prior to first administration of study drug., Age = 18 years., Histologically documented diagnosis of locally-advanced OR limited metasized intrahepatic BTC not amenable to curative treatment (tumor resection or ablation), specified as • Tumor being confined to the liver or • In case of presence of extrahepatic lesions, metastasis must be stable AND of limited extent*AND patient must have a potential benefit from study participation in comparison to standard of care systemic therapy per local tumor board evaluation. *Limited extent is defined in this protocol as presence of o EITHER =3 malignant extrahepatic lymph nodes (short axis diamete
排除标准
- •Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study, or during the follow-up period of an interventional study., Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, , serious active, uncontrolled, gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring AEs or compromise the ability of the patient to give written informed consent., History of non-infectious pneumonitis requiring steroids, or patients with Grade = 2 pneumonitis., History of another primary malignancy except for: o Malignancy treated with curative intent and with no known active disease = 5 years before the first dose of IP and of low potential risk for recurrence o Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease o Adequately treated carcinoma in situ without evidence of disease, History of leptomeningeal carcinomatosis, Brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have a CT/ MRI of the brain prior to study entry., History of active primary immunodeficiency, History of allogenic organ transplantation., Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), or human immunodeficiency virus (positive HIV 1/2 antibodies) or active hepatitis B/hepatitis C co-infection., Current or prior use of immunosuppressive medication within 14 days before the first dose of durvalumab or tremelimumab. The following are exceptions to this criterion: o Intranasal, inhaled, topical steroids, or local steroid injections (e.g. intra articular injection) o Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent o Steroids as premedication for hypersensitivity reactions (e.g. CT scan premedication), Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ highly effective birth control from screening to 180 days after the last dose of durvalumab., Participation in another clinical study with an investigational product within 21 days prior to the first dose of the study treatment., Known allergy or hypersensitivity to any of the IMPs or any of the constituents of the product., Any co-existing medical condition that in the investigator’s judgement will substantially increase the risk associated with the patient’s participation in the study., Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG., Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG]., Receipt of live attenuated vaccine within 30 days prior to the first administration of any of the IMPs and without need to receive any live attenuated vaccines during study conduct and for up to 30 days after end of Durvalumab treatment or 90 days after end of Tremelimumab treatment respectively., Prior immun
研究者
相似试验
已完成
不适用
Phase 2b study of combined immunotherapy with dinutuximab, interleukin-2, and G-CSF for high risk neuroblastomahigh risk neuroblastomaJPRN-UMIN000023009Osaka City General Hospital35
进行中（未招募）
2 期
A CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF PT 107 (VACCINE) IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTSCTRI/2010/091/001348PIQUE THERAPEUTICS INC100
已完成
2 期
ADJUBIL - A Phase II study of immunotherapy with durvalumab and tremelimumab in combination with capecitabine or without capecitabine in ADJUvant situation for BILiary tract cancer2024-511847-24-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH40
招募中
2 期
IMMUWIN - A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with Y-90 SIRT
for intermediate stage HCC2024-513950-32-00Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH55
进行中（未招募）
1 期
A phase II study of immunotherapy with durvalumab (MEDI4736) or durvalumab and tremelimumab, both combined with Y-90 SIRT therapy in patients with advanced stage intrahepatic biliary tract cancer (BTC) scheduled to receive Y-90 SIRT therapy as standard of careIntrahepatic Biliary Tract CarcinomaMedDRA version: 20.0Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864MedDRA version: 20.0Level: LLTClassification code 10073077Term: Intrahepatic cholangiocarcinomaSystem Organ Class: 100000004864EUCTR2018-004778-81-DEInstitut für Klinische Krebsforschung IKF GmbH50